BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, April 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2020

View Archived Issues

Prying mantis identifies disease genes

Read More

T-cell mutations contribute to GvHD

Read More

TLR5 is a therapeutic target for treating chronic colonic hypersensibility

Read More

NIH initiates ACTT 2 study of remdesivir plus baricitinib in patients with COVID-19

Read More

Novel peptide-targeted approach improves potency of anticancer drugs

Read More

PK and PD data presented for OPL-002 in healthy volunteers

Read More

CPU-025 demonstrates promising efficacy in mouse model of diabetes

Read More

Array BioPharma discloses new PTPN11 inhibitors

Read More

Dana-Farber Cancer Institute, Voronoi patent wild-type and mutant LRRK2 inhibitors

Read More

New histone-lysine N-methyltransferase SMYD3 inhibitors identified at Epizyme

Read More

Wild-type and mutant RET inhibitors identified at Medshine Discovery

Read More

Dual adenosine A2A/A2B receptor antagonists described by Merck KGaA

Read More

Via gene therapy, follistatin fights fat's fallout

Read More

New POLG genetic variant found in SANDO syndrome

Read More

ONSET-2 trial of OC-01 in dry eye disease meets primary endpoint

Read More

Phase III study of mavacamten in obstructive hypertrophic cardiomyopathy meets endpoints

Read More

Kiniksa reports data on mavrilimumab for COVID-19 and vixarelimab for pruritus

Read More

Boehringer Ingelheim studies BI-456906 for type 2 diabetes in new phase II trial

Read More

Canakinumab studied in phase III for CRS in patients with COVID-19-induced pneumonia

Read More

Enrollment underway for first-in-human study of BRAF inhibitor ABM-1310 in advanced solid tumors

Read More

Ustekinumab efficacy demonstrated in pediatric Crohn's disease patients

Read More

Phase I study of BRD4 inhibitor SYHA-1801 begins for advanced solid tumors

Read More

FDA clears IND for phase Ib/IIa study of HST-001 for androgenic alopecia

Read More

Phase III study of Sarclisa in relapsed multiple myeloma meets primary endpoint

Read More

Genfit reports phase III interim data on elafibranor in NASH

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 20, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • Novel caspase-2 inhibitor shows in vivo neuroprotective effects

    BioWorld Science
    Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing